贝伐珠单抗对晚期结肠癌化疗患者免疫功能及毒副反应的影响

Effect of bevacizumab on immune function and side effects of patients with advanced colon cancer chemotherapy

目的探讨贝伐珠单抗对晚期结肠癌化疗患者免疫功能及毒副反应的影响。方法选取我院收治的晚期结肠癌患者94例,按单盲法分为对照组和试验组,每组47例。对照组采用FOLFOX方案化疗,试验组在此基础上予以贝伐珠单抗治疗。连续化疗4个周期,比较两组临床疗效、免疫功能、毒副反应。结果化疗后,试验组总缓解率、CD3^+、CD3^+CD4^+、CD3^+CD8^+水平均较对照组高,P<0.05;试验组毒副反应发生率略低于对照组,两组比较P>0.05。结论FOLFOX方案化疗联合贝伐珠单抗可提升晚期结肠癌的治疗效果,提升患者免疫功能,且毒副反应少,安全性高。

Objective To explore the effect of bevacizumab on immune function and side effects of patients with advanced colon cancer chemotherapy.Methods A total of 94 patients with advanced colon cancer admitted to our hospital were enrolled and divided into the control group and the experimental group,47 cases in each group.The control group was treated with FOLFOX regimen.On this basis,the experimental group was treated with bevacizumab.Continuous chemotherapy for 4 weeks,the clinical efficacy,immune function,toxicity and side effects of the two groups were compared.Results After chemotherapy,the total remission rate,CD3^+,CD3^+CD4^+,CD3^+CD8^+ levels in the experimental group were higher than those in the control group,the difference was statistically significant (P<0.05).The incidence of toxic and side effects in the experimental group was slightly lower than that in the control group.However,the difference was not statistically significant (P>0.05).Conclusion FOLFOX regimen combined with bevacizumab can improve the therapeutic effect of advanced colon cancer,improve the immune function and have less toxicity and high safety.